VOR insider trading
NasdaqGS HealthcareVor Biopharma Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Vor Biopharma Inc.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company website: www.vorbio.com
VOR insider activity at a glance
FilingIQ has scored 210 insider transactions for VOR since Feb 9, 2021. The most recent filing in our index is dated Apr 22, 2026.
Across the full history, 7 open-market purchases
and 93 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VOR insider trades is 55.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VOR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding VOR
Frequently asked
- How many insider trades does FilingIQ track for VOR?
- FilingIQ tracks 210 Form 4 insider transactions for VOR (Vor Biopharma Inc.), covering filings from Feb 9, 2021 onwards. 15 of those were filed in the last 90 days.
- Are VOR insiders net buyers or net sellers?
- Across the full Form 4 history for VOR, 7 transactions (3%) were open-market purchases and 93 (44%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VOR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is VOR in?
- Vor Biopharma Inc. (VOR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $537.27M.
Methodology & sources
Every VOR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.